| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | KCNH6 |
| Uniprot No | Q9H252 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-502aa |
| 活性数据 | MPVRRGHVAPQNTYLDTIIRKFEGQSRKFLIANAQMENCAIIYCNDGFCELFGYSRVEVMQQPCTCDFLTGPNTPSSAVSRLAQALLGAEECKVDILYYRKDASSFRCLVDVVPVKNEDGAVIMFILNFEDLAQLLAKCSSRSLSQRLLSQSFLGSEGSHGRPGGPGPGTGRGKYRTISQIPQFTLNFVEFNLEKHRSSSTTEIEIIAPHKVVERTQNVTEKVTQVLSLGADVLPEYKLQAPRIHRWTILHYSPFKAVWDWLILLLVIYTAVFTPYSAAFLLSDQDESRRGACSYTCSPLTVVDLIVDIMFVVDIVINFRTTYVNTNDEVVSHPRRIAVHYFKGWFLIDMVAAIPFDLLIFRTGSDETTTLIGLLKTARLLRLVRVARKLDRYSEYGAAVLFLLMCTFALIAHWLACIWYAIGNVERPYLEHKIGWLDSLGVQLGKRYNGSDPASGPSVQDKYVTALYFTFSSLTSVGFGNVSPNTNSEKVFSICVMLIGCE |
| 分子量 | 80.96 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人KCNH6蛋白的3篇代表性文献(内容基于研究领域典型方向模拟概括，若需真实文献请告知)：
1. **文献名称**：*Expression and Functional Characterization of Recombinant Human KCNH6 in Mammalian Cells*
**作者**：Liu Y. et al. (2021)
**摘要**：通过哺乳动物细胞表达系统成功表达重组人KCNH6蛋白，并分析其在细胞膜上的定位及电压门控钾离子通道功能，证实其参与细胞动作电位的调控。
2. **文献名称**：*Structural Insights into KCNH6 Channel Gating by Cryo-EM*
**作者**：Zhang R. et al. (2023)
**摘要**：利用冷冻电镜技术解析重组人KCNH6蛋白的高分辨率三维结构，揭示其门控机制及与疾病相关突变位点的潜在关联，为靶向药物设计提供依据。
3. **文献名称**：*KCNH6 Loss-of-Function Mutations Impair Insulin Secretion in Human Pancreatic β-Cells*
**作者**：Wang H. et al. (2020)
**摘要**：通过重组KCNH6蛋白模型研究功能缺失突变体对胰岛素分泌的影响，发现KCNH6异常表达可能导致2型糖尿病中β细胞功能障碍。
4. **文献名称**：*High-Throughput Screening of KCNH6 Modulators Using Recombinant Protein Assays*
**作者**：Chen L. et al. (2022)
**摘要**：基于重组KCNH6蛋白建立药物筛选平台，鉴定多种小分子化合物对通道活性的调控作用，为心血管及代谢疾病治疗提供潜在候选药物。
(注：以上文献为模拟概括，如需真实文献需通过PubMed/Google Scholar检索关键词“recombinant KCNH6”或“KCNH6 channel”获取。)
Recombinant human KCNH6 protein is a genetically engineered form of the potassium voltage-gated channel subfamily H member 6. a key component of voltage-gated potassium channels. These channels regulate electrical signaling in excitable cells, such as neurons and cardiac myocytes, by controlling potassium ion flow across membranes. KCNH6. also known as hERG2. belongs to the ether-à-go-go (EAG) family, characterized by roles in action potential repolarization and cellular excitability. Structurally, it comprises six transmembrane domains with a pore-forming region and a cyclic nucleotide-binding homology domain, critical for voltage sensing and channel gating.
Research highlights KCNH6's involvement in insulin secretion regulation in pancreatic β-cells and cardiac electrophysiology. Dysfunctional KCNH6 channels are linked to metabolic disorders (e.g., diabetes) and arrhythmias. Producing recombinant KCNH6 enables detailed biochemical studies, drug screening, and structural analyses (e.g., cryo-EM) to elucidate its activation/inhibition mechanisms. Recombinant expression systems (e.g., HEK293 cells) facilitate high-yield, purified protein for functional assays, aiding therapeutic development targeting channelopathies. Its study bridges molecular biology, physiology, and translational medicine, offering insights into ion channel-related diseases and precision drug design.
×
